3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.

For a fourth approach of quinoxaline N,N'-dioxides as anti-trypanosomatid agents against T. cruzi and Leishmania, we found extremely active derivatives. The present study allows us to state the correct requirements for obtaining optimal in vitro anti-T. cruzi activity. Derivatives possessing electron-withdrawing substituents in the 2-, 3-, 6-, and 7-positions were the most active compounds. With regard to these features and taking into account their mammal cytotoxicity, some trifluoromethylquinoxaline N,N'-dioxides have been proposed as candidates for further clinical studies. Consequently, mutagenicity and in vivo analyses were performed with the most promising derivatives. In addition, with regard to the mechanism of action studies, it was demonstrated that mitochondrial dehydrogenases are involved in the anti-T. cruzi activity of the most active derivatives.

[1]  E. Castro,et al.  Anti-T. cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides. , 2010, Bioorganic & medicinal chemistry letters.

[2]  A. Denicola,et al.  Mode of action of nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved? , 2010, Biochemical pharmacology.

[3]  S. Zacchino,et al.  Naftifine-analogues as anti-Trypanosoma cruzi agents. , 2010, European journal of medicinal chemistry.

[4]  K. Gates,et al.  DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide. , 2010, Bioorganic & medicinal chemistry.

[5]  Auguste Genovesio,et al.  Antileishmanial High-Throughput Drug Screening Reveals Drug Candidates with New Scaffolds , 2010, PLoS neglected tropical diseases.

[6]  R. Villar,et al.  New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. , 2010, Bioorganic & medicinal chemistry.

[7]  A. Monge,et al.  Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. , 2003, European journal of medicinal chemistry.

[8]  R. Villar,et al.  Heterocyclic-2-carboxylic Acid (3-Cyano-1,4-di-N-oxidequinoxalin-2-yl)amide Derivatives as Hits for the Development of Neglected Disease Drugs , 2009, Molecules.

[9]  L. M. Lima,et al.  Selective activity against Mycobacteriumtuberculosis of new quinoxaline 1,4-di-N-oxides. , 2009, Bioorganic & medicinal chemistry.

[10]  M. Bertinaria,et al.  Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies. , 2008, Bioorganic & medicinal chemistry.

[11]  L. M. Lima,et al.  Synthesis and structure-activity relationship of 3-phenylquinoxaline 1,4-di-N-oxide derivatives as antimalarial agents. , 2008, European journal of medicinal chemistry.

[12]  J. Cazzulo,et al.  New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle. , 2008, Bioorganic & Medicinal Chemistry.

[13]  S. Franzblau,et al.  Efficacy of Quinoxaline-2-Carboxylate 1,4-Di-N-Oxide Derivatives in Experimental Tuberculosis , 2008, Antimicrobial Agents and Chemotherapy.

[14]  H. Cerecetto,et al.  Imidazolidines as new anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships. , 2008, Bioorganic & medicinal chemistry.

[15]  R. Villar,et al.  Substitutions of Fluorine Atoms and Phenoxy Groups in the Synthesis of Quinoxaline 1,4-di-N-oxide Derivatives† , 2007, Molecules.

[16]  L. M. Lima,et al.  Unexpected Reduction of Ethyl 3-Phenylquinoxaline-2-carboxylate 1,4-Di-N-oxide Derivatives by Amines† , 2007, Molecules.

[17]  R. Villar,et al.  Synthesis and Antiplasmodial Activity of 3-Furyl and 3-Thienylquinoxaline-2-carbonitrile 1,4-Di-N-oxide Derivatives † , 2008, Molecules.

[18]  Johann Gasteiger,et al.  Modeling anti-Trypanosoma cruzi Activity of N-Oxide Containing Heterocycles , 2008, J. Chem. Inf. Model..

[19]  M. Sauvain,et al.  Antiplasmodial structure-activity relationship of 3-trifluoromethyl-2-arylcarbonylquinoxaline 1,4-di-N-oxide derivatives. , 2008, Experimental parasitology.

[20]  A. Azqueta,et al.  Comparative Acute Systemic Toxicity of Several Quinoxaline 1,4-Di-N-oxides in Wistar Rats , 2007, Arzneimittelforschung.

[21]  A. Caligiani,et al.  Identification and quantification of the main organic components of vinegars by high resolution 1H NMR spectroscopy. , 2007, Analytica chimica acta.

[22]  A. Rojas de Arias,et al.  2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents. , 2006, Journal of medicinal chemistry.

[23]  V. Arán,et al.  Indazole N-oxide derivatives as antiprotozoal agents: synthesis, biological evaluation and mechanism of action studies. , 2006, Bioorganic & medicinal chemistry.

[24]  E. Barreiro,et al.  New potent 5-substituted benzofuroxans as inhibitors of Trypanosoma cruzi growth: quantitative structure-activity relationship studies. , 2005, Bioorganic & medicinal chemistry.

[25]  M. Chatterjee,et al.  Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. , 2005, Parasitology international.

[26]  A. Monge,et al.  Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents. , 2005, Journal of medicinal chemistry.

[27]  Mercedes González.  Novel Antiprotozoal Products: Imidazole and Benzimidazole N-Oxide Derivatives and Related Compounds. , 2004 .

[28]  H. Cerecetto,et al.  Quinoxaline N,N'-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships. , 2004, Bioorganic & medicinal chemistry letters.

[29]  A. Monge,et al.  Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives. , 2004, Bioorganic & medicinal chemistry.

[30]  T. Baltz,et al.  Detection of an “epimastigote-like” intracellular stage ofTrypanosoma cruzi , 2004, Parasitology Research.

[31]  J. Berman.  Current treatment approaches to leishmaniasis , 2003, Current opinion in infectious diseases.

[32]  A. Monge,et al.  Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. , 2003, European journal of medicinal chemistry.

[33]  A. Giménez,et al.  Anti-malarial activity of some 7-chloro-2-quinoxalinecarbonitrile-1,4-di-N-oxide derivatives. , 2003, Die Pharmazie.

[34]  É. Rosenthal,et al.  Recent understanding in the treatment of visceral leishmaniasis. , 2003, Journal of postgraduate medicine.

[35]  A. Monge,et al.  Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. , 2003, Bioorganic & medicinal chemistry.

[36]  H. Cerecetto,et al.  Chemotherapy of Chagas' disease: status and new developments. , 2002, Current topics in medicinal chemistry.

[37]  Shyam Sundar,et al.  Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. , 2002, The Lancet. Infectious diseases.

[38]  A. Denicola,et al.  Benzo[1, 2‐c]1, 2, 5‐oxadiazole N‐Oxide Derivatives as Potential Antitrypanosomal Drugs. Structure‐Activity Relationships. Part II , 2002, Archiv der Pharmazie.

[39]  I. Tirapu,et al.  Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. , 2001, Die Pharmazie.

[40]  A. Gómez-Barrio,et al.  Setting of a colorimetric method to determine the viability of Trypanosoma cruzi epimastigotes , 2000, Parasitology Research.

[41]  A. Romanha,et al.  In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. , 2000, The Journal of antimicrobial chemotherapy.

[42]  W. Colli,et al.  Trypanosoma cruzi: characterization of an intracellular epimastigote-like form. , 1999, Experimental parasitology.

[43]  G. Peluffo,et al.  1,2,5-Oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships. , 1999, Journal of medicinal chemistry.

[44]  C. Fernández-Becerra,et al.  Biochemical characterisation of flagellates isolated from fruits and seeds from Brazil , 1999 .

[45]  A. López de Cerain,et al.  Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitriles. , 1998, Farmaco.

[46]  A. Tielens,et al.  Differences in energy metabolism between trypanosomatidae. , 1998, Parasitology today.

[47]  P. Petit,et al.  In VivoInterference of Paromomycin with Mitochondrial Activity ofLeishmania , 1997 .

[48]  P. Petit,et al.  In vivo interference of paromomycin with mitochondrial activity of Leishmania. , 1997, Experimental cell research.

[49]  D. Sereno,et al.  Use of an enzymatic micromethod to quantify amastigote stage of Leishmania amazonensis in vitro , 1997, Parasitology Research.

[50]  A. Osuna,et al.  Activity and mode of action of acridine compounds against Leishmania donovani , 1996, Antimicrobial agents and chemotherapy.

[51]  A. Osuna,et al.  Metabolic studies by 1H NMR of different forms of Trypanosoma cruzi as obtained by 'in vitro' culture. , 1995, FEMS microbiology letters.

[52]  L. Filardi,et al.  Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. , 1987, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[53]  P. H. Griffiths,et al.  Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment , 1985, Veterinary Record.

[54]  B. Ames,et al.  Revised methods for the Salmonella mutagenicity test. , 1983, Mutation research.

[55]  R. Tarone,et al.  Evaluating statistical analyses and reproducibility of microbial mutagenicity assays. , 1981, Mutation research.